LONDON, March 16 (Reuters) - Adding GlaxoSmithKline Plc's top-selling drug Advair to Pfizer Inc's Spiriva does not reduce exacerbations in patients with COPD, or smoker's lung, according to new ...
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
LONDON (Reuters) - GlaxoSmithKline's top-selling respiratory drug Advair is set to lose business to Spiriva, marketed by Pfizer and Boehringer Ingelheim, according to analysts at Morgan Stanley. Sign ...
October 27, 2006 (Salt Lake City) -- New findings from the landmark Towards a Revolution in COPD Health (TORCH) study show that high-dose inhaled fluticasone propionate 500 mg/salmeterol 50 mg ( ...
Inhalers like Spiriva and Advair are too expensive for many Medicare beneficiaries with chronic obstructive pulmonary disease, reports Kaiser Health News. Here are four things to know. 1.
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results